TrialThe Lancet. Infectious diseases2022

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

Florence Ader et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.